Remove 2009 Remove Drug Development Remove Vaccines
article thumbnail

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

PharmaTech

cancer and vaccines), and non-immunogenic applications (e.g., cancer and vaccines), and non-immunogenic applications (e.g., Several types of mRNA-based vaccines have emerged, namely non-replicating linear mRNAs (NRM), self-amplifying mRNAs (saRNAs), and circular mRNAs (circRNAs). Types of messenger RNA (mRNA)-based vaccines.

article thumbnail

GRIN Therapeutics: Seeking to address unmet needs in rare neurodevelopmental disorders

pharmaphorum

Can you give a brief overview of why the historical development of new treatments for neurodevelopmental disorders has faced significant challenges? With the right teams and experience in place, drug developers can unlock their full potential, streamline efforts to advance them quickly, and bring more, new options to patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

article thumbnail

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

pharmaphorum

“There’s a lot that drug development for more common diseases could learn from rare disease R&D”. I think there’s a lot that drug development for more common diseases could learn from rare disease R&D.”. We have to be innovative to get around those challenges. Rare diseases during COVID. About the author.

Hospitals 111
article thumbnail

Top 20 Radiopharma Companies Based on Market Cap

PharmaShots

Market Cap: $8.57M Founded Year: 2009 Total Employees: ~40 Headquarters: Oslo, Norway Stock Exchange: OSE Nordic Nanovector is a biotech company committed to developing and commercializing antibody-radionuclide conjugates to address significant unmet medical needs.

Dosage 56
article thumbnail

A history of AstraZeneca

pharmaphorum

However, it withdrew its neuropharmacological drug, Zelmid, which was an SSRI, due to concerns over side effects only a year after it was introduced in 1982. In 1990, the US Food and Drug Administration (FDA) requested Astra to change Losec’s brand name to Prilosec, to avoid confusion with Sanofi-Aventis’ diuretic, Lasix (furosemide).

Vaccines 116
article thumbnail

Quality first: How pharma can meet injectables demand while staying compliant

Pharmaceutical Technology

Several drug development trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry.